SK281405B6 - Terapeutický prípravok na transdermálnu aplikáciu účinných látok - Google Patents
Terapeutický prípravok na transdermálnu aplikáciu účinných látok Download PDFInfo
- Publication number
- SK281405B6 SK281405B6 SK558-98A SK55898A SK281405B6 SK 281405 B6 SK281405 B6 SK 281405B6 SK 55898 A SK55898 A SK 55898A SK 281405 B6 SK281405 B6 SK 281405B6
- Authority
- SK
- Slovakia
- Prior art keywords
- active substances
- skin
- hmg
- increase
- therapeutic preparation
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 10
- 239000013543 active substance Substances 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 3
- 238000010521 absorption reaction Methods 0.000 claims abstract description 9
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims abstract description 7
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims abstract description 7
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims abstract description 7
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 7
- 229960004844 lovastatin Drugs 0.000 claims description 7
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 7
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- 229950009116 mevastatin Drugs 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 11
- 239000004615 ingredient Substances 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 11
- 239000003524 antilipemic agent Substances 0.000 description 8
- 230000004888 barrier function Effects 0.000 description 8
- 239000003623 enhancer Substances 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 231100000245 skin permeability Toxicity 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- -1 for example Chemical compound 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19541260A DE19541260A1 (de) | 1995-11-06 | 1995-11-06 | Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut |
| PCT/EP1996/004138 WO1997017061A1 (de) | 1995-11-06 | 1996-09-21 | Therapeutische zubereitung zur transdermalen applikation von wirkstoffen durch die haut |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK55898A3 SK55898A3 (en) | 1998-11-04 |
| SK281405B6 true SK281405B6 (sk) | 2001-03-12 |
Family
ID=7776710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK558-98A SK281405B6 (sk) | 1995-11-06 | 1996-09-21 | Terapeutický prípravok na transdermálnu aplikáciu účinných látok |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6379696B1 (cs) |
| EP (1) | EP0859595B1 (cs) |
| JP (1) | JP2001507331A (cs) |
| KR (1) | KR100445940B1 (cs) |
| CN (1) | CN1201385A (cs) |
| AT (1) | ATE186209T1 (cs) |
| AU (1) | AU716896B2 (cs) |
| CZ (1) | CZ289143B6 (cs) |
| DE (2) | DE19541260A1 (cs) |
| ES (1) | ES2141534T3 (cs) |
| GR (1) | GR3032523T3 (cs) |
| IL (1) | IL124279A (cs) |
| MX (1) | MX9803563A (cs) |
| MY (1) | MY132407A (cs) |
| NO (1) | NO982006D0 (cs) |
| NZ (1) | NZ318783A (cs) |
| PL (1) | PL326497A1 (cs) |
| PT (1) | PT859595E (cs) |
| SK (1) | SK281405B6 (cs) |
| WO (1) | WO1997017061A1 (cs) |
| ZA (1) | ZA969271B (cs) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19830732B4 (de) * | 1998-07-09 | 2008-11-13 | Lts Lohmann Therapie-Systeme Ag | Zusammensetzung, enthaltend mindestens einen die Blutfettwerte beeinflussenden Wirkstoff und seine Verwendung |
| NZ524646A (en) * | 2000-09-08 | 2004-10-29 | Alza Corp | Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure |
| US20020187169A1 (en) * | 2001-05-11 | 2002-12-12 | Shoujun Chen | Kavalactone compositions |
| EP1651197A1 (en) * | 2003-07-28 | 2006-05-03 | ALZA Corporation | Transdermal warfarin-containing delivery system |
| US20070166360A1 (en) * | 2004-03-31 | 2007-07-19 | Kowa Co., Ltd. | External preparation |
| PL2018153T3 (pl) | 2006-04-26 | 2012-09-28 | Rosemont Pharmaceuticals Ltd | Ciekłe kompozycje doustne |
| WO2007140191A2 (en) | 2006-05-23 | 2007-12-06 | Theracos, Inc. | Glucose transport inhibitors and methods of use |
| US8748419B2 (en) | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
| US7893053B2 (en) | 2006-06-16 | 2011-02-22 | Theracos, Inc. | Treating psychological conditions using muscarinic receptor M1 antagonists |
| US7652767B2 (en) * | 2006-10-19 | 2010-01-26 | Sporian Microsystems, Inc. | Optical sensor with chemically reactive surface |
| US20080152592A1 (en) * | 2006-12-21 | 2008-06-26 | Bayer Healthcare Llc | Method of therapeutic drug monitoring |
| US20100210932A1 (en) * | 2007-03-20 | 2010-08-19 | Bayer Healthcare Llc | Method of analyzing an analyte |
| AU2008232419B2 (en) | 2007-04-02 | 2013-06-20 | Theracos, Inc. | Benzylic glycoside derivatives and methods of use |
| NZ583369A (en) | 2007-08-23 | 2011-08-26 | Theracos Inc | Benzylbenzene derivatives and methods of use |
| US9061060B2 (en) | 2008-07-15 | 2015-06-23 | Theracos Inc. | Deuterated benzylbenzene derivatives and methods of use |
| PL2324002T3 (pl) | 2008-08-22 | 2017-03-31 | Theracos Sub, Llc | Sposoby otrzymywania inhibitorów sglt2 |
| EP2379561B1 (en) | 2008-11-25 | 2015-11-04 | University Of Rochester | Mlk inhibitors and methods of use |
| WO2010150100A1 (en) | 2009-06-24 | 2010-12-29 | Entarco Sa | The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer |
| JP5927506B2 (ja) | 2010-04-13 | 2016-06-01 | レルマダ セラピューティクス、インク． | １−メチル−２’，６’−ピペコロキシリダイドの皮膚医薬組成物および使用方法 |
| NZ603644A (en) | 2010-05-24 | 2014-10-31 | Univ Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
| WO2011153712A1 (en) | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
| WO2012085683A1 (en) | 2010-12-22 | 2012-06-28 | Entarco Sa | The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents |
| WO2012112933A1 (en) | 2011-02-18 | 2012-08-23 | The Scripps Research Institute | Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate |
| WO2014085795A1 (en) | 2012-11-30 | 2014-06-05 | University Of Rochester | Mixed lineage kinase inhibitors for hiv/aids therapies |
| US9420820B2 (en) | 2013-08-09 | 2016-08-23 | University Of Tsukuba | Method for isolating polyphenols from olive mill water |
| WO2015143240A2 (en) | 2014-03-19 | 2015-09-24 | Curza Global, Llc | Compositions and methods comprising 2-(acylamino)imidazoles |
| JP2020512981A (ja) | 2017-03-31 | 2020-04-30 | カーザ グローバル，リミティド ライアビリティ カンパニー | 置換２−アミノイミダゾールを含む組成物と方法 |
| AU2019324170A1 (en) | 2018-08-23 | 2021-02-18 | Seagen, Inc. | Anti-TIGIT antibodies |
| EP4240415A1 (en) | 2020-11-08 | 2023-09-13 | Seagen Inc. | Combination-therapy antibody drug conjugate with immune cell inhibitor |
| IL307556A (en) | 2021-04-09 | 2023-12-01 | Seagen Inc | Cancer treatment methods using antibodies against TIGIT |
| WO2024191807A1 (en) | 2023-03-10 | 2024-09-19 | Seagen Inc. | Methods of treating cancer with anti-tigit antibodies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3634016A1 (de) * | 1986-04-17 | 1987-10-29 | Lohmann Gmbh & Co Kg | Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung |
| US5211947A (en) * | 1988-12-16 | 1993-05-18 | Schering Corporation | Method for lowering blood cholesterol levels with granulocyte-macrophage colony stimulating factor |
| US5316765A (en) * | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
| WO1991015241A1 (fr) * | 1990-03-30 | 1991-10-17 | Yasunori Morimoto | Composition absorbable par voie percutanee d'analgesiques narcotiques et non narcotiques . |
| IL109037A (en) * | 1993-03-19 | 1999-01-26 | Cellegy Pharma Inc | Preparations for causing phase separation of lipid layers and preparation of the above preparations |
| DE4341444C2 (de) * | 1993-12-04 | 1996-03-14 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges Pflaster und Verfahren zu seiner Herstellung |
| US5968983A (en) * | 1994-10-05 | 1999-10-19 | Nitrosystems, Inc | Method and formulation for treating vascular disease |
-
1995
- 1995-11-06 DE DE19541260A patent/DE19541260A1/de not_active Withdrawn
-
1996
- 1996-09-21 IL IL12427997A patent/IL124279A/xx not_active IP Right Cessation
- 1996-09-21 PT PT96931820T patent/PT859595E/pt unknown
- 1996-09-21 WO PCT/EP1996/004138 patent/WO1997017061A1/de not_active Ceased
- 1996-09-21 DE DE59603597T patent/DE59603597D1/de not_active Expired - Lifetime
- 1996-09-21 CN CN96198113A patent/CN1201385A/zh active Pending
- 1996-09-21 AT AT96931820T patent/ATE186209T1/de active
- 1996-09-21 CZ CZ19981366A patent/CZ289143B6/cs not_active IP Right Cessation
- 1996-09-21 JP JP51777797A patent/JP2001507331A/ja active Pending
- 1996-09-21 US US09/068,326 patent/US6379696B1/en not_active Expired - Lifetime
- 1996-09-21 SK SK558-98A patent/SK281405B6/sk unknown
- 1996-09-21 AU AU70859/96A patent/AU716896B2/en not_active Ceased
- 1996-09-21 EP EP96931820A patent/EP0859595B1/de not_active Expired - Lifetime
- 1996-09-21 PL PL96326497A patent/PL326497A1/xx unknown
- 1996-09-21 KR KR10-1998-0703316A patent/KR100445940B1/ko not_active Expired - Fee Related
- 1996-09-21 ES ES96931820T patent/ES2141534T3/es not_active Expired - Lifetime
- 1996-09-21 NZ NZ318783A patent/NZ318783A/en unknown
- 1996-11-04 MY MYPI96004590A patent/MY132407A/en unknown
- 1996-11-05 ZA ZA969271A patent/ZA969271B/xx unknown
-
1998
- 1998-05-04 NO NO982006A patent/NO982006D0/no not_active Application Discontinuation
- 1998-05-06 MX MX9803563A patent/MX9803563A/es not_active IP Right Cessation
-
2000
- 2000-01-31 GR GR20000400219T patent/GR3032523T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1201385A (zh) | 1998-12-09 |
| NO982006L (no) | 1998-05-04 |
| MX9803563A (es) | 1998-09-30 |
| AU716896B2 (en) | 2000-03-09 |
| NZ318783A (en) | 1999-04-29 |
| AU7085996A (en) | 1997-05-29 |
| DE59603597D1 (de) | 1999-12-09 |
| KR19990067320A (ko) | 1999-08-16 |
| WO1997017061A1 (de) | 1997-05-15 |
| CZ136698A3 (cs) | 1998-07-15 |
| ZA969271B (en) | 1997-06-03 |
| NO982006D0 (no) | 1998-05-04 |
| KR100445940B1 (ko) | 2005-09-30 |
| US6379696B1 (en) | 2002-04-30 |
| EP0859595A1 (de) | 1998-08-26 |
| SK55898A3 (en) | 1998-11-04 |
| GR3032523T3 (en) | 2000-05-31 |
| MY132407A (en) | 2007-10-31 |
| EP0859595B1 (de) | 1999-11-03 |
| DE19541260A1 (de) | 1997-05-07 |
| ES2141534T3 (es) | 2000-03-16 |
| JP2001507331A (ja) | 2001-06-05 |
| PT859595E (pt) | 2000-04-28 |
| CZ289143B6 (cs) | 2001-11-14 |
| IL124279A (en) | 2003-07-06 |
| PL326497A1 (en) | 1998-09-28 |
| ATE186209T1 (de) | 1999-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK281405B6 (sk) | Terapeutický prípravok na transdermálnu aplikáciu účinných látok | |
| EP2521453B1 (en) | Combinations of vitamin d and a statin for the treatment of migraine headaches | |
| US8435556B2 (en) | Transdermal delivery of cannabidiol | |
| JP5184342B2 (ja) | 外用の医薬組成物 | |
| WO1997035576A1 (en) | Use of isoniazid for the treatment of hyperlipoproteinemia | |
| WO2007102241A1 (ja) | 外用の医薬組成物 | |
| MA26960A1 (fr) | Sels d'un isothiazole-4-carboxamide et leur utilisation comme agent anti-hyperproliferation | |
| US4197318A (en) | Potentiated antimicrobial medicaments | |
| MXPA04009819A (es) | Reduccion de crecimiento de vello. | |
| CN119367341A (zh) | 采用ralinepag与其他药剂的组合治疗pah的方法 | |
| MXPA01000126A (es) | Compuesto que contiene por lo menos un principio activo que incide en el indice de grasa en la sangre. | |
| US4474748A (en) | Medicaments potentiated with phenyl alkanols | |
| SK73996A3 (en) | Transdermal therapeutical system | |
| JP3040427B2 (ja) | 神経痛治療用アスピリン含有軟膏組成物 | |
| EP2570123A1 (en) | Use of 2,4-dichlorobenzyl alcohol having an anaesthetic effect | |
| JPWO2004026297A1 (ja) | 外用剤 | |
| US20190117585A1 (en) | A device for the transdermal delivery of buprenorphine | |
| AU2019319213A1 (en) | Compositions and methods for treatment of the side-effects associated with administration of therapeutic agents | |
| Mitani et al. | Fluvastatin, HMG‐CoA Reductase Inhibitor: Antiatherogenic Profiles Through Its Lipid‐Lowering–Dependent and‐Independent Actions | |
| CA2499620A1 (en) | External preparation containing acetylsalicylic acid for inhibiting keloid formation | |
| AU9385098A (en) | Intranasal formulation containing scopolamine and method of treating motion sickness | |
| KR0176319B1 (ko) | 알킬화제로 인한 피부 손상 치료용 조성물 | |
| JP3050917B2 (ja) | 経皮投与基剤組成物とその薬剤組成物 | |
| WO2009080301A1 (en) | Treatment and prevention of ischaemic cerebral lesions and cerebrovascular cognitive impairment using a treatment regimen consisting of dipyridamole and an angiotensin ii receptor blocker in patients with previous stroke | |
| Arifov et al. | Acitretin (neotigason) in the treatment of psoriasis |